title: [Surgical treatment options in end-stage heart failure].
abstract: Despite significant improvements in pharmacological therapy heart failure is still one of the leading causes for death in the Western World. The gold standard treatment of end-stage heart failure remains cardiac transplantation, but there is a great excess of eligible candidates compared with the low number of suitable donor organs. The variety of surgical organ preserving treatment strategies has significantly increased during the last 20 years, intenting either to delay or even to prevent the need for cardiac transplantation. An individually tailored surgical concept should be considered as an alternative in any heart failure patient who has reached the limits of pharmacologic therapy. This article gives an overview about current and potential future therapeutic options in end-stage heart failure.
authors.affiliation: Klinik fur Herzchirurgie, Universitatsspital Basel, Spitalstrasse 10, Basel-Bern. mgrapow@uhbs.ch
authors.forename: Martin T R
authors.initials: MT
authors.lastname: Grapow
authors.forename: Thierry P
authors.initials: TP
authors.lastname: Carrel
authors.forename: Friedrich S
authors.initials: FS
authors.lastname: Eckstein
mesh_terms: D002311:Cardiomyopathy, Dilated / Q000503:physiopathology / Q000601:surgery; D018421:Cardiomyoplasty; D002317:Cardiovascular Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006333:Heart Failure / Q000503:physiopathology / Q000601:surgery*; D016027:Heart Transplantation; D006352:Heart Ventricles / Q000503:physiopathology / Q000601:surgery*; D006353:Heart-Assist Devices; D006801:Humans; D008943:Mitral Valve / Q000503:physiopathology / Q000601:surgery*; D008944:Mitral Valve Insufficiency / Q000503:physiopathology / Q000601:surgery; D017202:Myocardial Ischemia / Q000503:physiopathology / Q000601:surgery; D009204:Myocardial Revascularization
chemical_list: D002317:Cardiovascular Agents